Comprehensive Clinical Reference for GCC Nurses | Updated 2025
The MSE is a structured assessment of a patient's current mental functioning. It is a cross-sectional snapshot — not a history. Document objectively; distinguish observed from reported.
| Positive (added experiences) | Negative (reduced function) |
|---|---|
| Hallucinations | Flat / blunted affect |
| Delusions | Alogia (poverty of speech) |
| Disorganised speech | Avolition (lack of motivation) |
| Disorganised behaviour | Anhedonia (no pleasure) |
| Thought disorder | Social withdrawal |
| Catatonic features | Cognitive impairment |
| Type | Description |
|---|---|
| Persecutory | Being followed, harmed, conspired against |
| Grandiose | Inflated importance, power, identity |
| Nihilistic | Belief that self/world does not exist (Cotard's) |
| Somatic | False belief about body function/disease |
| Reference | Events/people have special meaning for patient |
Overvalued ideas: Strongly held, understandable, some flexibility — e.g., extreme health anxiety.
Obsessions: Ego-dystonic, intrusive, patient resists — e.g., contamination fears in OCD.
| Drug | Notes |
|---|---|
| Haloperidol | High-potency; high EPS risk; IM available for acute use |
| Chlorpromazine | Low-potency; sedating; anticholinergic effects |
| Drug | Key Nursing Points |
|---|---|
| Olanzapine | Metabolic syndrome risk; weight gain, hyperglycaemia |
| Risperidone | Dose-related EPS; prolactin elevation; available as depot |
| Aripiprazole | Partial agonist; lower metabolic risk; akathisia possible |
| Quetiapine | Sedating; useful for sleep; retinal monitoring needed |
| Clozapine | Treatment-resistant schizophrenia; see dedicated section |
| Phase | FBC Frequency |
|---|---|
| Weeks 1–18 | Weekly |
| Weeks 19–52 | Bi-weekly (every 2 weeks) |
| After 1 year | Monthly |
Annual monitoring for all patients on antipsychotics (especially clozapine, olanzapine, quetiapine):
| Parameter | Target / Action Level |
|---|---|
| Weight / BMI | Baseline, 1 month, 3 months, then annually |
| Blood Pressure | >140/90 — refer to physician |
| Fasting Glucose | >7.0 mmol/L — diabetes screen |
| HbA1c | >48 mmol/mol = diabetes |
| Fasting Lipids | Total cholesterol >5.0 mmol/L — intervention |
| Waist circumference | M >102cm / F >88cm = high risk |
| Score | Severity | Action |
|---|---|---|
| 0–4 | Minimal | Monitor; lifestyle advice |
| 5–9 | Mild | Watchful waiting; psychoeducation |
| 10–14 | Moderate | Antidepressant + therapy; MDT review |
| 15–19 | Mod-Severe | Active medication; urgent therapy |
| 20–27 | Severe | Urgent psychiatric review; hospitalise |
| Level | Range | Meaning |
|---|---|---|
| Therapeutic | 0.6–1.0 mmol/L | Maintenance dose |
| High therapeutic | 0.8–1.0 mmol/L | Acute mania |
| Caution | 1.0–1.5 mmol/L | Monitor closely |
| Toxicity | >1.5 mmol/L | Mild-moderate toxic |
| Severe toxicity | >2.0 mmol/L | Emergency |
| Ideation Type | Risk Level |
|---|---|
| Wish to be dead (passive) | Low |
| Active ideation, no method | Low-Med |
| Active ideation with method | Medium |
| Ideation with intent but no plan | High |
| Ideation with plan AND intent | High |
| Level | Description | Frequency |
|---|---|---|
| General | In the ward environment | Hourly whereabouts known |
| Intermittent | Location checked | Every 15–30 min |
| Within Eyesight | Always visible to nurse | Continuous line-of-sight |
| 1:1 | One nurse, one patient | Within arm's reach |
| 2:1 | Two nurses, one patient | High aggression/self-harm |
| Letter | Question | Score |
|---|---|---|
| P | Problems for more than 1 month? | Yes = 1 |
| A | Attending to alcohol problems? | Yes = 1 |
| T | Treatment — psychiatric patient? | Yes = 1 |
| H | Hopelessness — does the future seem hopeless? | Yes = 1 |
| O | Others — others would be better off if you died? | Yes = 1 |
| S | Suicidal intent at the time? | Yes = 1 |
Active listening. Reflect back. Validate feelings. Do not dismiss or argue with the patient's reality.
Offer choices where possible: "Would you like to sit down / have water / go to a quieter space?" Restoring control reduces agitation.
Observe non-verbal cues: clenching fists, pacing, voice escalation. These signal escalation. Act early — before aggression peaks.
Match your communication level to the patient — simple sentences, calm tone, slow pace. Avoid jargon. Use first name respectfully.
Identify the trigger or unmet need: pain, fear, confusion, perceived disrespect. Address the root cause, not just the behaviour.
Non-threatening posture: open hands, side-on stance, personal space (1.5–2m). No direct eye-contact stare. Lower your voice.
Explain what you are doing and why. Transparency builds trust. Avoid sudden actions or touching without warning.
| Drug | Dose |
|---|---|
| Lorazepam | 1–2 mg PO |
| Haloperidol | 5 mg PO |
| Olanzapine (wafer) | 10 mg ODT |
| Promethazine | 25–50 mg PO |
| Drug | Dose |
|---|---|
| Lorazepam IM | 1–2 mg IM |
| Haloperidol IM | 5 mg IM |
| Promethazine IM | 25–50 mg IM |
| Olanzapine IM | 10 mg IM |
The CHIME framework describes the key processes of personal recovery in mental health. Nurses facilitate recovery by supporting each domain.
Peer support groups, community connections, therapeutic relationship with care team, family involvement. Isolation worsens all mental health conditions.
Believing recovery is possible. Nurses reinforce hope through positive language, sharing recovery stories, goal-setting. Avoid prognosis statements that close down hope.
Help the patient reclaim identity beyond their diagnosis. "A person with schizophrenia" not "a schizophrenic." Strengths-based approach.
Finding purpose through meaningful activity, spirituality, work, relationships. In GCC context: integration of Islamic faith as source of meaning and resilience.
Shared decision-making, advance statements, patient-led care planning. Nurses advocate for patient choices — avoid paternalistic approaches.
| Boundary | Guideline |
|---|---|
| Time | Fixed appointment times; end sessions on time; punctuality models reliability |
| Place | Therapeutic work in designated settings; avoid casual social encounters |
| Self-Disclosure | Minimal, purposeful only — to build rapport; never personal problems |
| Gifts | Decline or manage carefully; small cultural gifts — discuss in supervision |
| Physical contact | Professional only; document any incidental contact; cultural awareness in GCC |
| Social media | Never accept patient friend requests; maintain professional separation |
| Country | Key Law | Key Feature |
|---|---|---|
| UAE | Federal MHL 2020 | Rights-based framework; voluntary/involuntary admission; legal safeguards; appeals tribunal |
| Saudi Arabia | Mental Health Law (Royal Decree) | Patient rights charter; forensic provisions; involuntary admission criteria |
| Qatar | Mental Health Care Act (NHSQ) | Capacity-based framework; MHT review; patients' rights |
| Kuwait | Law No. 53/1996 | Psychiatric facility regulation; criminal responsibility provisions |
| Bahrain | DPM regulations | MOPH oversight; voluntary/compulsory admission pathways |
Integration with Nursing Care: Islamic faith is a primary coping mechanism for many patients in GCC. Quran recitation (ruqyah), prayer (salah), and remembrance of God (dhikr) have documented psychological benefit and are culturally consonant with recovery.
For clinical decision support only. This tool does not replace clinical judgement. Always involve the MDT for any identified risk.
UAE: Dubai Mental Health Helpline: 800-HOPE (4673) | Abu Dhabi: 800-4673
Saudi Arabia: Ministry of Health Mental Health Line: 920033360
Qatar: Hamad Mental Health Helpline: 16000 | Crisis: 999
Kuwait: Mental Health Department: 1880 | Emergency: 112
Bahrain: King Hamad University Hospital Psychiatry: +973 17 444444
Oman: Khoula Hospital Psychiatry: +968 24564400 | Emergency: 9999
For inpatient nurses: always contact on-call psychiatrist directly for any high or imminent risk. Do not rely solely on helplines for admitted patients.
Advanced Psychiatric & Mental Health Nursing Guide — GCC Edition | For qualified nurses. Not a substitute for clinical judgement, local protocols, or MDT decision-making.
References: C-SSRS (Columbia University), CHIME (Leamy et al.), LOWLINE model, GCC Mental Health Laws 2020–2024, WHO mhGAP.